Opendata, web and dolomites

VSV-EBOPLUS SIGNED

SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "VSV-EBOPLUS" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.vsv-eboplus.eu
 Total cost 15˙430˙660 €
 EC max contribution 8˙553˙750 € (55%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-08-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 1˙625˙000.00
2    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 1˙698˙750.00
3    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 1˙696˙875.00
4    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 1˙645˙000.00
5    Centre de Recherches Medicales de Lambaréné GA (Lambaréné) participant 701˙250.00
6    MICROBIOTEC SRL IT (MONTERIGGIONI) participant 485˙000.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 395˙625.00
8    UNIVERSIDADE DE SAO PAULO BR (SAO PAULO SP) participant 306˙250.00
9    EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT CH (BERN) participant 0.00
10    MERCK SHARP & DOHME CORP US (WHITEHOUSE STATION NJ) participant 0.00
11    UNIVERSITE DE GENEVE CH (GENEVE) participant 0.00

Map

 Project objective

The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine “take”, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US).

Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children. We propose: 1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOV;

 Deliverables

List of deliverables.
Distribution of samples (serum, plasma, Paxgene tubes) to partners involved in immunogenicity / transcriptomic studies Documents, reports 2019-10-07 17:33:12

Take a look to the deliverables list in detail:  detailed list of VSV-EBOPLUS deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Angela Huttner, Claire-Anne Siegrist
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582
Expert Review of Vaccines 17/12 2019-10-07
2018 Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Correlates of vaccine-induced protective immunity against Ebola virus disease
published pages: , ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003
Seminars in Immunology 2019-10-07
2018 Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÄHLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, José F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8
The Lancet Infectious Diseases 18/7 2019-10-07

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VSV-EBOPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More